Comment
doi: 10.1016/S0140-6736(23)01182-0.
Epub 2023 Jun 26.
A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
Affiliations
- PMID: 37385276
- DOI: 10.1016/S0140-6736(23)01182-0
Item in Clipboard
Comment
A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
Lancet.
.
No abstract available
Conflict of interest statement
SCB has received honoraria for presentations from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Roche, and Sanofi-Aventis, broadly related to GLP-1 receptor agonists for the treatment of diabetes, and travel expenses from Eli Lilly and Novo Nordisk. TM has received honoraria for presentations from Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, and Napp, broadly related to GLP-1 receptor agonists for the treatment of diabetes, and travel expenses from Napp. Eli Lilly is the sponsor of retatrutide and tirzepatide and Eli Lilly, Novo Nordisk, and Sanofi manufacture drugs based on GLP-1.
Comment on
-
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385280 Clinical Trial.
Similar articles
-
Incretins: their physiology and application in the treatment of diabetes mellitus.Diabetes Metab Res Rev. 2014 Jul;30(5):354-71. doi: 10.1002/dmrr.2501. Diabetes Metab Res Rev. 2014. PMID: 24989141 Review.
-
Incretin Physiology and Pharmacology in the Intensive Care Unit.Crit Care Clin. 2019 Apr;35(2):341-355. doi: 10.1016/j.ccc.2018.11.011. Epub 2019 Jan 24. Crit Care Clin. 2019. PMID: 30784614 Review.
-
The role of incretin-based therapies in the management of type 2 diabetes.Drug News Perspect. 2009 Nov;22(9):559-67. doi: 10.1358/dnp.2009.22.9.1434633. Drug News Perspect. 2009. PMID: 20072733
-
Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?Eur J Endocrinol. 2008 Jun;158(6):773-84. doi: 10.1530/EJE-07-0804. Epub 2008 Mar 5. Eur J Endocrinol. 2008. PMID: 18322302 Review.
-
Addition of incretin therapy to metformin in type 2 diabetes.Lancet. 2010 Apr 24;375(9724):1410-2. doi: 10.1016/S0140-6736(10)60399-6. Lancet. 2010. PMID: 20417840 No abstract available.
Cited by
-
12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.EClinicalMedicine. 2024 Jul 10;74:102726. doi: 10.1016/j.eclinm.2024.102726. eCollection 2024 Aug. EClinicalMedicine. 2024. PMID: 39764175 Free PMC article.
-
Time to Insulin Therapy and Severe Hypoglycemia in Korean Adults Initially Diagnosed with Type 2 Diabetes: A Nationwide Study.Endocrinol Metab (Seoul). 2025 Jun;40(3):421-433. doi: 10.3803/EnM.2024.2082. Epub 2025 Feb 4. Endocrinol Metab (Seoul). 2025. PMID: 39901809 Free PMC article.
-
Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes.J Am Coll Cardiol. 2025 May 20;85(19):1858-1872. doi: 10.1016/j.jacc.2025.03.516. Epub 2025 Mar 30. J Am Coll Cardiol. 2025. PMID: 40368575
-
Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.NPJ Metab Health Dis. 2025;3(1):10. doi: 10.1038/s44324-025-00054-5. Epub 2025 Mar 14. NPJ Metab Health Dis. 2025. PMID: 40094000 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
